Heart Rhythm Daily - Day 1, 2008 - (Page 2)

Theodore Chow, M.D., FACC Electrophysiologist, The Ohio Heart & Vascular Center; Director, Electrophysiology Research for Carl & Edyth Linder Clinical Trials Center Medicare has issued a National Coverage Decision covering Spectral Analytic Method™ Microvolt T-Wave Alternans™ (MTWA) testing broadly for the evaluation of patients at risk for sudden cardiac death. “I recommend MTWA testing of primary prevention ICD candidates (LVEF ≤ 35%) when: • The patient is reluctant to undergo ICD implantation without additional proof of risk; • The patient has a borderline LVEF for ICD qualiﬁcation; or • The time horizon for ICD beneﬁt is reduced, for example by signiﬁcant co-morbidities or advanced age. Since the great majority of sudden cardiac deaths occur in patients with LVEF above 35%, MTWA testing is also appropriate in my opinion for evaluating these patients when a clinical suspicion for risk is present, for example, syncope or non-sustained ventricular arrhythmias, particularly in those with LV dysfunction and prior myocardial infraction.” ACC/AHA/ESC Class IIa Guideline - Level of Evidence A REIMBURSEMENT INCLUDES: Medicare, BCBS*, CIGNA, Aetna & Humana www.cambridgeheart.com 888.CAM.WAVE *Check with your local provider. Microvolt T-Wave Alternans™ and Spectral Analytic Method™ are trademarks of Cambridge Heart, Inc. Copyright 2008, Inc. All rights reserved. Come Visit us at Booth Number 1829 http://www.cambridgeheart.com http://www.cambridgeheart.com

Table of Contents Feed for the Digital Edition of Heart Rhythm Daily - Day 1, 2008

Contents Opening Plenary Hands-on Session AF Summit Update

Heart Rhythm Daily - Day 1, 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.